EVAX News and Press, Evaxion Biotech A/S From 05/07/24

NEW YORK, NY / ACCESSWIRE / May 7, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Conference taking place Wednesday and Thursday, May 8-9, 2024. The presentation schedule is subject to change...

Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing Favorable safety profile confirmed Trial on track for one-year clinical efficacy readout in Q3 2024 COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S ...

2024-04-02 14:10:02 ET Evaxion Biotech A/S (EVAX) Q4 2023 Results Conference Call April 02, 2024 09:00 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chi...

Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infections The vaccine antigens significantly protected large, non-rodent animals against surgical site infections, indicating promisi...

2024-03-31 06:39:26 ET Summary Evaxion's sophisticated AI Immunology platform aims to outperform competitors in vaccine development, in both oncology and infectious diseases indications. The company has already established three collaborations, including a partnership with MSD, an...

2024-03-27 13:49:48 ET More on Evaxion Biotech ADS Evaxion Biotech to raise ~$15M through public offering of shares and warrants Evaxion stock rallies 120% on AI-based cancer vaccine program Seeking Alpha’s Quant Rating on Evaxion Biotech ADS Historica...

Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named endogenous retroviruses (ERVs), broadening the potential of cancer vaccines. Successful completi...

The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologies AI-Immunology™ outcompetes standard vaccine target discovery approaches and holds the promise of addressing...

COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announces that it will host a Research &...

COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine coll...